Here are 10 questions that will determine how well the Avalanche does in 2013-14.
1. "Will Patrick Roy really be ready to coach in the NHL?" ? I say yes, yes, a thousand times yes. He's paid his dues. He's ready for his close-up behind the bench. He's going to be very good at this.
2. "What will be the one thing that most accelerates some dark hairs to gray?" ? The defense. It won't be great. Patrick will have to spin a few plates and get the smoke and mirrors just right to make that defense adequate.
3. "Ryan O'Reilly will be a left winger. Is this the wrong decision?" ? Could be. He's been a center his whole life, but now he'll be expected to be the one who changes position for the good of the team. But with Paul Stastny, Matt Duchene and Nathan MacKinnon already here as centers, O'Reilly was the odd-man out.
4. "If O'Reilly doesn't play well, is it a foregone conclusion he'll be traded later in the season?" ? Not necessarily. Both he and Stastny are entering their final contract years, but the Avs would retain O'Reilly's rights after this coming season ends. Not so with Stastny. He can become an unrestricted free agent. If they don't think the numbers on a future deal add up, Stastny would be prime trade bait at the deadline.
5. "Doesn't it look like either Stastny or O'Reilly will have to go at some point soon?" ? Yeah, probably.
6. "Was it more than a little alarming the other day when new goalie coach Francois Allaire was quoted as saying he thinks, after talking with him, that Semyon Varlamov wants to "flush everything out" and start over with new working concepts in goal?" ? Alarming? No, not necessarily. A
Avalanche coach Patrick Roy (John Leyba, Denver Post file)
tad worrisome? Perhaps, but overall I think it's a good thing Varlamov wants to submit to his new teacher with a mind-set of "let's try anything, if it will work." Allaire has a proven track record of turning around the careers of previous goalies, so this development could be one of the best of the summer for the Avs.
7. "Who should be captain of the Avs?" ? With no offense to Gabe Landeskog, I think Matt Duchene has emerged as the real leader of this team. Landeskog would make a great alternate captain, but there were too many things last season that hinted the young Swede was not quite ready. Exhibit A: It should have been Landeskog who went off in the locker room after a late-season, desultory loss to Calgary. Instead, it was left to J.S. Giguere to do it. Maybe Jiggy should really get the "C," except they don't allow goalies to be captains in the NHL.
8. "Is Erik Johnson training himself silly right now, looking like Clubber Lang in 'Rocky III,' ready to prove everyone he's champion material?" ? Just wonderin'.
9. "Is the new Jumbotron going to make going to the Pepsi Center a much better experience?" ? I hear it'll be semi-mind blowing.
10. "How hard will it be to get through all of August with zero hockey talk while you are on vacation?" ? Tough, very tough. But I'll figure out some way to compensate on a beach on Cape Cod very soon.
Until then ... I'll send you all a postcard.
Adrian Dater: 303-954-1360, adater@denverpost.com or twitter.com/adater
Visit denverpost.com each weekday near noontime for a serving of dish concerning Colorado's sporting landscape from a Denver Post sports writer. Care for another helping? Visit the Lunch Special archive.
Bitly is announcing that Mark Josephson, who was most recently senior vice president of Patch Labs at AOL, has joined the link shortening and tracking company as its new CEO. Peter Stern, who served as CEO for about a year, stepped down in March to "pursue other interests." (Chief scientist Hilary Mason also left recently to become data scientist in residence at venture firm Accel Partners.)
Source: www.egyptindependent.com --- Monday, July 29, 2013 Supporters of Egypt's ousted Islamist President marched toward a military facility in defiance of an army warning in the early hours of Monday, risking a new confrontation after dozens were shot dead at the weekend. The Muslim Brotherhood said the destination was the military intelligence headquarters, despite an army statement warning protesters to steer clear of military installations. A Reuters reporter saw several thousand marchers leaving the Rabea al-Adaweya mosque in northern Cairo, where they have been staging a weeks-long vigil to demand the reinstatement of deposed Mohamed Morsy, Egypt's first freely elected President. At least 72 Brotherhood supporters were shot dead by security forces on Saturday near the vigil, deepening the turmoil convulsing the country since the army shunted Morsy from power on 3 July. The killings at dawn, following a day of rival mass rallies, fuelled global anxiety that the Arab world's most populous nation - a bridge between the Middle East and North Africa - risked broader conflagration. The European Union's foreign policy chief, Catherine Ashton, was due to meet on Monday in Cairo with the army's General Abdel Fattah al-Sisi, who led the overthrow of Morsy, and officials of the Freedom and Justice Party, the Brotherhood's political wing. The marchers carried pictures of the deposed President, flashing victory signs and chanting, "Our blood and souls we sacrifice for Morsy." The military inte ...
New modular vaccine design combines best of existing vaccine technologiesPublic release date: 29-Jul-2013 [ | E-mail | Share ]
Contact: Meghan Weber meghan.weber@childrens.harvard.edu 617-919-3110 Boston Children's Hospital
MAPS technology may generate vaccines conferring strong immunity at reduced cost and risk
Boston, Mass.A new method of vaccine design, called the Multiple Antigen Presentation System (MAPS), may result in vaccines that bring together the benefits of whole-cell and acellular or defined subunit vaccination. The method, pioneered by researchers at Boston Children's Hospital, permits rapid construction of new vaccines that activate mulitple arms of the immune system simultaneously against one or more pathogens, generating robust immune protection with a lower risk of adverse effects.
As reported by Fan Zhang, PhD, Ying-Jie Lu, PhD, and Richard Malley, MD, from Boston Children's Division of Infectious Disease, in the Proceedings of the National Academy of Sciences on July 29, the method could speed development of new vaccines for a range of globally serious pathogens, or infectious agents.
Broadly speaking, the vaccines available today fall into two categories: whole-cell vaccines, which rely on weakened or killed bacteria or viruses; and acellular or subunit vaccines, which include a limited number of antigensportions of a pathogen that trigger an immune response. Both approaches have advantages and disadvantages.
"Whole-cell vaccines elicit a broad range of immune responses, often just as an infection would, but can cause side effects and are hard to standardize," said Malley. "Acellular vaccines can provide good early immunity with less risk of side effects, but the immune responses they induce wane with time."
The MAPS method may allow vaccine developers to take a middle ground, where they can link multiple protein and polysaccharide (sugar) antigens from one or more pathogens together in a modular fashion, much as one would connect Lego blocks.
The resulting complexwhich resembles a scaffold of polysaccharides studded with proteinscan stimulate both antibody and T-cell responses simultaneously much like whole-cell vaccines, resulting in stronger immunity to the source pathogen(s). However, because the composition of a MAPS vaccine is well defined and based on the use of isolated antigens (as one would find with an acellular vaccine) the risk of side effects should be greatly reduced.
For instance, mice injected with a MAPS vaccine combining proteins from tuberculosis (TB) and polysaccharides from Streptococcus pneumoniae (pneumococcus) mounted vigorous antibody and T-cell responses against TB, whereas those vaccinated with TB protein antigens alone mounted only an antibody response.
Similarly, 90 percent of mice given a MAPS-based vaccine containing multiple pneumococcal polysaccharide and protein antigens were protected from a lethal pneumococcus infection, mounting strong antibody and T-cell responses against the bacteria. By contrast, 30 percent of mice vaccinated with the same antigens in an unbound state survived the same challenge.
"The MAPS technology gives you the advantages of: whole-cell vaccines while being much more deliberate about which antigens you include; doing it in a quantitative and precise way; and including a number of antigens so as to try to replicate the effectiveness of whole-cell vaccination," Malley explained. "The immunogenicity of these constructs is greater than the sum of their parts, somewhat because they are presented to the host as particles."
The system relies on the interactions of two compounds, biotin and rhizavidin, rather than covalent binding as is used in most of the current conjugate vaccines. To build a MAPS vaccine, biotin is bound to the polysaccharide(s) of choice and rhizavidin to the protein(s). The biotin and rhizavidin then bind together through an affinity interaction analogous to Velcro. The construction process is highly efficient, significantly reducing the time and cost of vaccine development and production.
While his team's initial work has focused on bacterial pathogens, Malley believes the technology could impact vaccine development for a broad range of pathogens, in particular those of importance in the developing world. "Technically, one could construct MAPS vaccines for viruses, parasites, even cancer antigens," he said. "And the modularity is such that one could include antigens from multiple pathogens into the same vaccine, allowing the development of combinatorial vaccines much more efficiently."
###
The study was supported by the National Institute for Allergy and Infectious Diseases (grant R01AI067737) and the Translational Research Program at Boston Children's Hospital.
Boston Children's Hospital is home to the world's largest research enterprise based at a pediatric medical center, where its discoveries have benefited both children and adults since 1869. More than 1,100 scientists, including seven members of the National Academy of Sciences, 13 members of the Institute of Medicine and 14 members of the Howard Hughes Medical Institute comprise Boston Children's research community. Founded as a 20-bed hospital for children, Boston Children's today is a 395-bed comprehensive center for pediatric and adolescent health care grounded in the values of excellence in patient care and sensitivity to the complex needs and diversity of children and families. Boston Children's is also the primary pediatric teaching affiliate of Harvard Medical School. For more information about research and clinical innovation at Boston Children's, visit: http://vectorblog.org.
[ | E-mail | Share ]
?
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.
New modular vaccine design combines best of existing vaccine technologiesPublic release date: 29-Jul-2013 [ | E-mail | Share ]
Contact: Meghan Weber meghan.weber@childrens.harvard.edu 617-919-3110 Boston Children's Hospital
MAPS technology may generate vaccines conferring strong immunity at reduced cost and risk
Boston, Mass.A new method of vaccine design, called the Multiple Antigen Presentation System (MAPS), may result in vaccines that bring together the benefits of whole-cell and acellular or defined subunit vaccination. The method, pioneered by researchers at Boston Children's Hospital, permits rapid construction of new vaccines that activate mulitple arms of the immune system simultaneously against one or more pathogens, generating robust immune protection with a lower risk of adverse effects.
As reported by Fan Zhang, PhD, Ying-Jie Lu, PhD, and Richard Malley, MD, from Boston Children's Division of Infectious Disease, in the Proceedings of the National Academy of Sciences on July 29, the method could speed development of new vaccines for a range of globally serious pathogens, or infectious agents.
Broadly speaking, the vaccines available today fall into two categories: whole-cell vaccines, which rely on weakened or killed bacteria or viruses; and acellular or subunit vaccines, which include a limited number of antigensportions of a pathogen that trigger an immune response. Both approaches have advantages and disadvantages.
"Whole-cell vaccines elicit a broad range of immune responses, often just as an infection would, but can cause side effects and are hard to standardize," said Malley. "Acellular vaccines can provide good early immunity with less risk of side effects, but the immune responses they induce wane with time."
The MAPS method may allow vaccine developers to take a middle ground, where they can link multiple protein and polysaccharide (sugar) antigens from one or more pathogens together in a modular fashion, much as one would connect Lego blocks.
The resulting complexwhich resembles a scaffold of polysaccharides studded with proteinscan stimulate both antibody and T-cell responses simultaneously much like whole-cell vaccines, resulting in stronger immunity to the source pathogen(s). However, because the composition of a MAPS vaccine is well defined and based on the use of isolated antigens (as one would find with an acellular vaccine) the risk of side effects should be greatly reduced.
For instance, mice injected with a MAPS vaccine combining proteins from tuberculosis (TB) and polysaccharides from Streptococcus pneumoniae (pneumococcus) mounted vigorous antibody and T-cell responses against TB, whereas those vaccinated with TB protein antigens alone mounted only an antibody response.
Similarly, 90 percent of mice given a MAPS-based vaccine containing multiple pneumococcal polysaccharide and protein antigens were protected from a lethal pneumococcus infection, mounting strong antibody and T-cell responses against the bacteria. By contrast, 30 percent of mice vaccinated with the same antigens in an unbound state survived the same challenge.
"The MAPS technology gives you the advantages of: whole-cell vaccines while being much more deliberate about which antigens you include; doing it in a quantitative and precise way; and including a number of antigens so as to try to replicate the effectiveness of whole-cell vaccination," Malley explained. "The immunogenicity of these constructs is greater than the sum of their parts, somewhat because they are presented to the host as particles."
The system relies on the interactions of two compounds, biotin and rhizavidin, rather than covalent binding as is used in most of the current conjugate vaccines. To build a MAPS vaccine, biotin is bound to the polysaccharide(s) of choice and rhizavidin to the protein(s). The biotin and rhizavidin then bind together through an affinity interaction analogous to Velcro. The construction process is highly efficient, significantly reducing the time and cost of vaccine development and production.
While his team's initial work has focused on bacterial pathogens, Malley believes the technology could impact vaccine development for a broad range of pathogens, in particular those of importance in the developing world. "Technically, one could construct MAPS vaccines for viruses, parasites, even cancer antigens," he said. "And the modularity is such that one could include antigens from multiple pathogens into the same vaccine, allowing the development of combinatorial vaccines much more efficiently."
###
The study was supported by the National Institute for Allergy and Infectious Diseases (grant R01AI067737) and the Translational Research Program at Boston Children's Hospital.
Boston Children's Hospital is home to the world's largest research enterprise based at a pediatric medical center, where its discoveries have benefited both children and adults since 1869. More than 1,100 scientists, including seven members of the National Academy of Sciences, 13 members of the Institute of Medicine and 14 members of the Howard Hughes Medical Institute comprise Boston Children's research community. Founded as a 20-bed hospital for children, Boston Children's today is a 395-bed comprehensive center for pediatric and adolescent health care grounded in the values of excellence in patient care and sensitivity to the complex needs and diversity of children and families. Boston Children's is also the primary pediatric teaching affiliate of Harvard Medical School. For more information about research and clinical innovation at Boston Children's, visit: http://vectorblog.org.
[ | E-mail | Share ]
?
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.
Several Japanese automakers have announced a joint project to install charging stations across their home country.
Toyota, Nissan, Honda and Mitsubishi will work with each other and existing charging companies to drastically increase the number of regular and quick chargers across Japan, paving the way for higher electric vehicle adoption.
The existing network of 1,700 fast chargers and just over 3,000 regular charging points will grow significantly, with plans for more than 4,000 fast chargers and over 8,000 regular stations.
These are likely to be spread among commercial facilities such as malls and restaurants, as well as highway service areas, parking areas, convenience stores and gas stations.
Other priorities drawn up in the agreement include bearing some of the cost involved with public charging stations and collaborating with existing networks to make charging points easier for any EV owner to use.
The latter may involve a universal card-based system allowing plug-in vehicle owners to use any of the thousands of charging points with the same card and regardless of their vehicle. Take note, rest-of-the-world...
In addition to paying for charging points and allowing all plug-in users to use them with minimal fuss, the automakers will also work with local governments and government agencies on ways to maximize electric vehicle use--with the eventual aim of electric cars making up 15-20 percent of new car sales by 2020.
In 2012, just under 3,400,000 new cars were sold in Japan (Source: BBC)--so the automakers and government are looking at 2020 plug-in car sales of over half a million.
The Japanese government itself has announced subsidies of 100.5 billion Yen ($15.3 million) for charging station installation in 2013, with each Japanese prefecture drawing up its own plans on how best to use these subsidies. Automakers will work together with local governments to ensure these stations are best sited for customers.
[unable to retrieve full-text content]ATLANTA ? The recent crowdfunding and venture-capital funds established by the state make Georgia a leader in creating ways for investors to support start-up companies, according to a team of industry veterans. The state ...
Henry Ford Estate celebrates auto icon's 150th birthday
Dearborn ? The Henry and Clara Ford estate at Fair Lane, which has been shuttered for two years, was reopened to the public Saturday for a celebration of the automotive icon's 150th birthday.
A link to this page will be included in your message.
Tom Nelson: Complete BS from Washington Post blogger Carter Eskew: "98 percent of global scientists" say "global warming is real, man-made, and an urgent crisis" skip to main | skip to sidebar
Complete BS from Washington Post blogger Carter Eskew: "98 percent of global scientists" say "global warming is real, man-made, and an urgent crisis"
The Insiders: On climate, too, the GOP is out of touch
This post won?t even try to convince deniers that global warming is real, man-made, and an urgent crisis. They have already rejected a consensus of 98 percent of global scientists who say it is all that. Rather, let?s argue the politics.
BEVERLY HILLS, Calif. (AP) ? AMC says it has ordered two new dramas that are expected to debut in 2014.
The cable channel said Friday that "Halt & Catch Fire" is set in the early 1980s and looks at the personal computing explosion through the eyes of a visionary engineer. It stars Lee Pace of TV's "Pushing Daisies" and the film "Lincoln."
The other drama, "Turn," is based on the book "Washington's Spies" by historian Alexander Rose. It stars Jamie Bell of the movie "Billy Elliot" and "King Kong."
"Turn" is set in 1778 and tells the story of a New York farmer who joins a group of spies fighting for American independence.
Back in February at the Mobile World Congress tradeshow a plethora of carriers pledged their support for Mozilla’s HTML-5 open web mobile platform, Firefox OS,?which is hoping to shake up the low-end smartphone segment. Today, the launch date of the first commercial Firefox OS phone has been confirmed: the ZTE Open will go on sale tomorrow in Spain, on Telefonica’s Movistar network. The handset will cost ?69 (around $90), which includes a pre-pay balance of??30 for prepaid customers plus a 4GB microSD card. The carrier is also offering an option of zero interest financing for post-paid customers. IHS Screen Digest analyst Ian Fogg described the pricing as “very compelling, commenting on the launch via?Twitter: “Featurephones are dead, finally…?Now there?s no price reason not to own a smartphone.” Telefonica said it also plans to offer the handset in additional markets “?in the coming weeks”?– name-checking?Colombia and Venezuela. When it announced ?support for Firefox OS?back in February it said its first Firefox-powered phones would be sold in Latin America and Spain. In the event, Spain gets first dibs.?Also today,?Telefonica confirmed the ZTE Open will be the first of “a number of Firefox OS devices” it will launch this year — “across a range of different price points”. Which suggests it’s also hoping to challenge Android’s expansive mid-tier, although this first handset sits firmly in the low end segment. Commenting on the launch in a statement, Luis Miguel Gilp?rez, CEO of Telef?nica Espa?a, said: ?We believe that smartphones need to be more open and that the web is the platform for making this possible. Consumers should not be locked to any one system but have the choice to consume the content they want and the flexibility to be able to take it with them when they change devices. This first open web device marks a significant milestone in making this possible. This is just the beginning as we plan to bring a wide range of Firefox OS devices to our customers.? This is not the only diversification effort Telefonica has made in the smartphone space in recent times. Just last week it announced a joint marketing effort with Microsoft to push the Windows Phone 8 platform?in a bid to dilute the power of Android and iOS. Firefox OS can be seen as another branch of the same strategy, as carriers seek ways to erode the dominance Google especially has established in smartphones. Figures